plasma protein inflammatory mediator systems include
Logo

Nursing Elites

ATI RN

MSN 570 Advanced Pathophysiology Final 2024

1. Which of the following correctly identifies the plasma protein inflammatory mediator systems?

Correct answer: C

Rationale: The correct answer is C: Complement, clotting, and kinin systems. These are the three main plasma protein inflammatory mediator systems. The complement system helps in inflammation and immune responses, the clotting system is involved in blood coagulation, and the kinin system regulates inflammation and blood pressure. Choice A is incorrect because interferon is not part of the plasma protein inflammatory mediator systems. Choice B is incorrect because the fibrinolytic system is not a primary inflammatory mediator system. Choice D is incorrect because acute phase reactants are not part of the plasma protein inflammatory mediator systems.

2. Which of the following factors are known to contribute to an individual's ability to adapt to stress? (Select ONE that does not apply.)

Correct answer: A

Rationale: The correct factors that contribute to an individual's ability to adapt to stress are age, socioeconomic status, and gender. Age can influence coping mechanisms and resilience. Socioeconomic status can impact access to resources and support systems. Gender differences can also play a role in how individuals experience and manage stress. Ethnicity, while important in other contexts, is not directly mentioned in the provided rationale and is not one of the factors listed as contributing to an individual's ability to adapt to stress.

3. Which of the following characteristics is common in both malignant and benign tumors?

Correct answer: A

Rationale: The correct answer is A: Uncontrolled cell growth. This characteristic is common to both malignant and benign tumors. Benign tumors are non-cancerous growths that do not invade nearby tissue or spread to other parts of the body. Therefore, choices B, C, and D are incorrect. Rapid growth, metastasis, and invasion of surrounding tissue are characteristics typically associated with malignant tumors.

4. A hospital patient's complex medical history includes a recent diagnosis of kidney cancer. Which of the following medications is used to treat metastatic kidney cancer?

Correct answer: B

Rationale: The correct answer is B: Aldesleukin (Proleukin). Aldesleukin is a medication used in the treatment of metastatic kidney cancer. It is a recombinant interleukin-2 that works by stimulating the immune system to attack cancer cells. Choice A, Filgrastim, is a medication used to stimulate the production of white blood cells. Choice C, Interferon alfa-2b, is used in the treatment of certain cancers but not specifically metastatic kidney cancer. Choice D, Darbepoetin alfa, is used to treat anemia by stimulating red blood cell production and is not indicated for metastatic kidney cancer.

5. Which of the following is not included in the care plan of a client with moderate cognitive impairment involving dementia of the Alzheimer’s type?

Correct answer: C

Rationale: In the care plan for a client with moderate cognitive impairment involving Alzheimer's type dementia, a stimulating environment is not included as it can potentially increase confusion. Therefore, it is important to provide a familiar, structured, and predictable environment to reduce stress and disorientation. Daily structured schedules help in maintaining routine and familiarity, positive reinforcement encourages engagement in activities, and validation techniques help in communicating effectively with the client by acknowledging their feelings and reality orientation.

Similar Questions

Which clients are at highest risk for pneumonia?
When reviewing the purpose/action of neurotransmitters as they interact with different receptors, the nursing instructor gives an example using acetylcholine. When acetylcholine is released at the sinoatrial node in the right atrium of the heart, it is:
A nurse is teaching a patient about the use of raloxifene (Evista) for the prevention of osteoporosis. What is the primary therapeutic action of this medication?
The unique clinical presentation of a 3-month-old infant in the emergency department leads the care team to suspect botulism. Which assessment question posed to the parents is likely to be most useful in the differential diagnosis?
A patient is being educated about the use of raloxifene (Evista) for osteoporosis. What is the primary therapeutic action of this medication?

Access More Features

ATI RN Basic
$69.99/ 30 days

  • 5,000 Questions with answers
  • All ATI courses Coverage
  • 30 days access

ATI RN Premium
$149.99/ 90 days

  • 5,000 Questions with answers
  • All ATI courses Coverage
  • 30 days access

Other Courses